David Whitrap, Institute for Clinical and Economic Review vice president of communications and outreach, in a recent post says some investors see beyond dollar signs.
Whitrap points to a report by Morningstar in which it gives AstraZeneca a nod for its efforts to make “smart strategic decisions on drug pricing.”
“The media often try to pit ICER against the pharmaceutical industry — cobra vs mongoose,” Whitrap writes. “But frankly, this portrayal is short-sighted and incomplete. Increasingly, the more forward-thinking biopharma companies are rolling up their sleeves to engage fully in ICER’s assessments.”
To read more, click here.
